Donor origin CAR T cells: Graft versus malignancy effect without GVHD, a systematic review

Faiz - Anwer, Al Aman Shaukat, Umar Zahid, Muhammad Husnain, Ali Mcbride, Daniel Persky, Melissa Lim, Nida Hasan, Irbaz Bin Riaz

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematological malignancies. Best results have been reported in acute lymphoblastic leukemia patients with a complete response rate above 80%. Patients who received donor-derived CAR T cells for the relapsed malignancy after stem cell transplantation (allogenic hematopoietic stem cell transplant) were identified from the published trials. A total of 72 patients from seven studies were treated with donor-derived CAR T cells. Only five out of 72 patients (6.9%) developed graft versus host disease. Use of donor-derived CAR T cell for relapse prophylaxis, minimal residual disease clearance or salvage from relapse is therefore highly effective, and risk of graft versus host disease flare is very low. Side effects include cytokine release syndrome, tumor lysis syndrome, B-cell aplasia along with CNS toxicity.

Original languageEnglish (US)
Pages (from-to)123-130
Number of pages8
JournalImmunotherapy
Volume9
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

T-Cell Antigen Receptor
Tissue Donors
Transplants
Graft vs Host Disease
Neoplasms
CD20 Antigens
Tumor Lysis Syndrome
Recurrence
Antigen Receptors
Hematopoietic Stem Cell Transplantation
Residual Neoplasm
Hematologic Neoplasms
Cell- and Tissue-Based Therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphocytes
Cytokines
T-Lymphocytes
Therapeutics

Keywords

  • allogenic stem cell transplantation
  • chimeric antigen T cells
  • graft versus leukemia
  • hematological malignancy
  • relapse
  • salvage

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Anwer, F. ., Shaukat, A. A., Zahid, U., Husnain, M., Mcbride, A., Persky, D., ... Riaz, I. B. (2017). Donor origin CAR T cells: Graft versus malignancy effect without GVHD, a systematic review. Immunotherapy, 9(2), 123-130. https://doi.org/10.2217/imt-2016-0127

Donor origin CAR T cells : Graft versus malignancy effect without GVHD, a systematic review. / Anwer, Faiz -; Shaukat, Al Aman; Zahid, Umar; Husnain, Muhammad; Mcbride, Ali; Persky, Daniel; Lim, Melissa; Hasan, Nida; Riaz, Irbaz Bin.

In: Immunotherapy, Vol. 9, No. 2, 01.01.2017, p. 123-130.

Research output: Contribution to journalReview article

Anwer, F, Shaukat, AA, Zahid, U, Husnain, M, Mcbride, A, Persky, D, Lim, M, Hasan, N & Riaz, IB 2017, 'Donor origin CAR T cells: Graft versus malignancy effect without GVHD, a systematic review', Immunotherapy, vol. 9, no. 2, pp. 123-130. https://doi.org/10.2217/imt-2016-0127
Anwer, Faiz - ; Shaukat, Al Aman ; Zahid, Umar ; Husnain, Muhammad ; Mcbride, Ali ; Persky, Daniel ; Lim, Melissa ; Hasan, Nida ; Riaz, Irbaz Bin. / Donor origin CAR T cells : Graft versus malignancy effect without GVHD, a systematic review. In: Immunotherapy. 2017 ; Vol. 9, No. 2. pp. 123-130.
@article{55b9f328c6474fe688ed1f522553a878,
title = "Donor origin CAR T cells: Graft versus malignancy effect without GVHD, a systematic review",
abstract = "CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematological malignancies. Best results have been reported in acute lymphoblastic leukemia patients with a complete response rate above 80{\%}. Patients who received donor-derived CAR T cells for the relapsed malignancy after stem cell transplantation (allogenic hematopoietic stem cell transplant) were identified from the published trials. A total of 72 patients from seven studies were treated with donor-derived CAR T cells. Only five out of 72 patients (6.9{\%}) developed graft versus host disease. Use of donor-derived CAR T cell for relapse prophylaxis, minimal residual disease clearance or salvage from relapse is therefore highly effective, and risk of graft versus host disease flare is very low. Side effects include cytokine release syndrome, tumor lysis syndrome, B-cell aplasia along with CNS toxicity.",
keywords = "allogenic stem cell transplantation, chimeric antigen T cells, graft versus leukemia, hematological malignancy, relapse, salvage",
author = "Anwer, {Faiz -} and Shaukat, {Al Aman} and Umar Zahid and Muhammad Husnain and Ali Mcbride and Daniel Persky and Melissa Lim and Nida Hasan and Riaz, {Irbaz Bin}",
year = "2017",
month = "1",
day = "1",
doi = "10.2217/imt-2016-0127",
language = "English (US)",
volume = "9",
pages = "123--130",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Donor origin CAR T cells

T2 - Graft versus malignancy effect without GVHD, a systematic review

AU - Anwer, Faiz -

AU - Shaukat, Al Aman

AU - Zahid, Umar

AU - Husnain, Muhammad

AU - Mcbride, Ali

AU - Persky, Daniel

AU - Lim, Melissa

AU - Hasan, Nida

AU - Riaz, Irbaz Bin

PY - 2017/1/1

Y1 - 2017/1/1

N2 - CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematological malignancies. Best results have been reported in acute lymphoblastic leukemia patients with a complete response rate above 80%. Patients who received donor-derived CAR T cells for the relapsed malignancy after stem cell transplantation (allogenic hematopoietic stem cell transplant) were identified from the published trials. A total of 72 patients from seven studies were treated with donor-derived CAR T cells. Only five out of 72 patients (6.9%) developed graft versus host disease. Use of donor-derived CAR T cell for relapse prophylaxis, minimal residual disease clearance or salvage from relapse is therefore highly effective, and risk of graft versus host disease flare is very low. Side effects include cytokine release syndrome, tumor lysis syndrome, B-cell aplasia along with CNS toxicity.

AB - CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematological malignancies. Best results have been reported in acute lymphoblastic leukemia patients with a complete response rate above 80%. Patients who received donor-derived CAR T cells for the relapsed malignancy after stem cell transplantation (allogenic hematopoietic stem cell transplant) were identified from the published trials. A total of 72 patients from seven studies were treated with donor-derived CAR T cells. Only five out of 72 patients (6.9%) developed graft versus host disease. Use of donor-derived CAR T cell for relapse prophylaxis, minimal residual disease clearance or salvage from relapse is therefore highly effective, and risk of graft versus host disease flare is very low. Side effects include cytokine release syndrome, tumor lysis syndrome, B-cell aplasia along with CNS toxicity.

KW - allogenic stem cell transplantation

KW - chimeric antigen T cells

KW - graft versus leukemia

KW - hematological malignancy

KW - relapse

KW - salvage

UR - http://www.scopus.com/inward/record.url?scp=85011085626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011085626&partnerID=8YFLogxK

U2 - 10.2217/imt-2016-0127

DO - 10.2217/imt-2016-0127

M3 - Review article

C2 - 28128714

AN - SCOPUS:85011085626

VL - 9

SP - 123

EP - 130

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 2

ER -